A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome

IMPROVE-IT: Enrollment and Study Period

IMPROVE-IT: Study Goals

PROVE-IT Trial

National Cholesterol Education Program Adult Treatment Panel III Guidelines

LDL Hypothesis: Is Lowering LDL Enough, or Does the Agent Matter?

ENHANCE: Ezetimibe/Simvastatin in Familial Hypercholesterolemia

Challenges Faced During IMPROVE-IT

Determinants of Atherosclerosis

CTT Meta-Analysis of 26 Trials: More Intensive Lowering of LDL-C

IMPROVE-IT: Lower LDL-C Level With Ezetimibe/Simvastatin Combination

IMPROVE-IT: Ezetimibe/Simvastatin Reduces Risk of Cardiovascular Events

Selection of End Points in Statin Trials

IMPROVE-IT: Subgroup Analysis 7-year Event Rates

No Increased Risk of Cancer With Ezetimibe

SHARP: Ezetimibe/Simvastatin Reduces Risk of Atherosclerotic Events in CKD

Statin Intolerance

IMPROVE-IT: Safety Data

Ezetimibe Target: NPC1L1-A Sterol Transporter

Genetic Targets in LDL-C Lowering: PCSK9

Early LDL-C Level Predicts Cardiovascular Disease

Genetic Targets in LDL-C Lowering APOB

Recommendations: Match Intensity of Therapy to Absolute Risk

JPPP: Low-Dose Aspirin in Elderly Japanese Patients With CV Risk Factors

Longer-Term Dual Antiplatelet Therapy Reduces Risk of MACCE

TNT Trial: Intensive Statin Therapy Reduces Risk of Cardiovascular Events

Primary Prevention

CCTA Does Not Reduce Cardiovascular Risk in High-Risk Patients With DM

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)